Stay updated on Niraparib-bev-Dostarlimab vs Niraparib-bev vs Std of Care Clinical Trial

Sign up to get notified when there's something new on the Niraparib-bev-Dostarlimab vs Niraparib-bev vs Std of Care Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Niraparib-bev-Dostarlimab vs Niraparib-bev vs Std of Care Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a three-arm randomized trial evaluating the efficacy of niraparib-bevacizumab-dostarlimab triplet combination against standard of care treatment for patients with recurrent ovarian cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:23.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for the study, including specific health conditions and prior treatments required for participation. This change offers more comprehensive information for potential participants and researchers monitoring the study.
    Difference
    46%
    Check dated 2024-05-22T20:59:49.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:23:42.000Z thumbnail image

Stay in the know with updates to Niraparib-bev-Dostarlimab vs Niraparib-bev vs Std of Care Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Niraparib-bev-Dostarlimab vs Niraparib-bev vs Std of Care Clinical Trial page.